ASCO 2026｜宗艾替尼一线治疗HER2突变NSCLC再添患者获益新证，辅助治疗III期研究未来可期

整理：肿瘤资讯

来源：肿瘤资讯

2026年美国临床肿瘤学会（ASCO）年会于5月29日至6月2日在芝加哥盛大召开，作为全球肿瘤领域最具影响力的学术盛会之一，多项重磅研究成果在此期间揭晓。在HER2突变非小细胞肺癌（NSCLC）领域，新一代高选择性HER2酪氨酸激酶抑制剂（TKI）宗艾替尼披露两项关键临床研究：Beamion LUNG-1研究队列2初治患者报告结局（PRO）^[1]与Beamion LUNG-3辅助治疗III期研究设计^[2]，进一步揭示了宗艾替尼在HER2突变晚期NSCLC一线治疗中的结局数据，并为其向早期辅助治疗领域拓展奠定基础。值此之际，特邀上海市胸科医院李子明教授，对这两项关键研究进行深度解读，并剖析宗艾替尼对HER2突变NSCLC治疗策略的临床价值。

调研问卷

审稿专家

李子明教授

上海交通大学医学院附属胸科医院肿瘤科主任
主任医师、肿瘤学博士、上海交通大学博士生导师
中华医学会肿瘤学分会青委委员
中国抗癌协会肿瘤免疫治疗委员会常务委员
中国临床肿瘤学会 (CSCO) 青委委员
美国纽约叶史瓦大学爱因斯坦医学院访问学者(2014.8-2015.9)
上海市青年拔尖人才、上海市优秀学术带头人
上海市浦江人才、上海市人才发展基金
主要研究方向为肺癌多学科综合治疗的基础与临床研究，擅长肺癌微创肿瘤消融术

审批号：SC-CN-18697

有效期至：2027年6月5日

仅供相关医药专业人士进行医学科学交流

参考文献

[1] Joshua K. Sabari, Gerrina Ruiter, Ernest Nadal, et al. PRO results from the Beamion LUNG-1 trial in treatment-naive patients with HER2-mutant advanced NSCLC. ASCO 2026. Abstract 8616 .

[2] Amy L. Cummings, Timothy D. Clay, Jay Lee, et al. Beamion LUNG-3: Zongertinib in Resectable HER2-Mutant NSCLC. ASCO 2026. TPS8129 .

[3] Heymach JV, Yamamoto N, Girard N, et al. First-Line Zongertinib in Advanced HER2-Mutant Non-Small-Cell Lung Cancer. N Engl J Med. 2026. 394(17): 1675-1684.

[4] John V. Heymach, Noboru Yamamoto, Nicolas Girard, et al. Zongertinib in Treatment-Naïve Patients With HER2-mutant NSCLC, Including Those With Active Brain Metastases: Beamion LUNG-1. 2026 ELCC. 6MO .

[5] Sanjay Popat, Noboru Yamamoto, Nicolas Girard, et al. Zongertinib as First-Line Treatment in Patients with Advanced HER2-Mutant NSCLC: Beamion LUNG-1. 2025 ESMO. LBA74 .

[6] Trillo Aliaga P, Spitaleri G, Attili I, et al. HER2 in Non-Small Cell Lung Cancer (NSCLC): Evolution of the Therapeutic Landscape and Emerging Drugs-A Long Way to the Top. Molecules. 2025. 30(12): 2645.

[7] Heymach JV, Ruiter G, Ahn MJ, et al. Zongertinib in Previously Treated HER2-Mutant Non-Small-Cell Lung Cancer. N Engl J Med. 2025. 392(23): 2321-2333.

[8] Wilding B, Woelflingseder L, Baum A, et al. Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers. Cancer Discov. 2025. 15(1): 119-138.

[9] John V. Heymach, Gerrina Ruiter, Myung-Ju Ahn, et al. Zongertinib in patients with pretreated HER2-mutant advanced NSCLC: Beamion LUNG-1. 2025 AACR. CT050 .

[10] G. Ruiter, E.F. Smit, R.A. Soo, et al. Zongertinib in Patients With Previously Treated HER2-Mutant NSCLC and Brain Metastases at Baseline: Beamion LUNG-1. 2025 WCLC. PT2.12.03

[11] Joshua K. Sabari, Ernest Nadal, Lizza Hendriks, et al. Patient-reported outcomes (PRO) evaluating physical functioning and symptoms in patients with pretreated HER2-mutant advanced non-small cell lung cancer (NSCLC): Results from the Beamion LUNG-1 trial. 2025 ASCO. Abstract 8620 .

[12] NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Non Small Cell Lung Cancer. Version 5. 2026 .

[13] 中国临床肿瘤学会（CSCO). CSCO非小细胞肺癌诊疗指南2026.

排版编辑：niko

责任编辑：CY